CFDE Data Portal | Search ANKFN1

	Label	Description
	ANKFN1 Gene (Entity type)	ENSG00000153930 - ankyrin repeat and fibronectin type III domain containing 1
	ANKFN1 associations Collection (Entity type)	Associations for ANKFN1_associations
	ANKFN1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	GSE216043 7 V 9 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE135350 2 V 4 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE102467 3 V 2 PAZOPANIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE101239 5 V 6 VALPROIC ACID MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE164874 5 V 10 PREDNISOLONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

ANKFN1

ENSG00000153930 - ankyrin repeat and fibronectin type III domain containing 1

ANKFN1 associations

Associations for ANKFN1_associations

ANKFN1 associations.tsv

A file from IDG as part of the Harmonizome project

GSE216043 7 V 9 CISPLATIN HUMAN DN

A Gene Set from LINCS

GSE135350 2 V 4 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE102467 3 V 2 PAZOPANIB HUMAN UP

A Gene Set from LINCS

GSE101239 5 V 6 VALPROIC ACID MOUSE UP

A Gene Set from LINCS

GSE164874 5 V 10 PREDNISOLONE HUMAN DN

A Gene Set from LINCS

GSE189653,GSE203344 5 V 3 FLUOXETINE MOUSE UP

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.